Company news

Neurizon Therapeutics Limited news in 2017

Neurizon Therapeutics Limited's news releases, calls and decks from 2017, newest first.

View company

Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit

December 12, 2017

PharmAust Raises $1.873m via an Oversubscribed Placement

December 5, 2017

New MPL analogues show greater anti-cancer activity

November 22, 2017

New drugs patented for cancer in USA

November 15, 2017

Epichem Update - progress on milestones and revenue targets

October 31, 2017

Appendix 4C - Quarterly Report & Brief Company Update

October 26, 2017

Monepantel reformulation project continues to progress

October 16, 2017

New patent secured in US for non-cancer applications

October 9, 2017

Reformulation project achieves first milestones and on-track

September 19, 2017

PharmAust secures core Europe patent

September 11, 2017

PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement

September 3, 2017

Appendix 4E & Full Year Statutory Accounts 2017

August 31, 2017

PharmAust Shareholders Update

August 21, 2017

Epichem reports record $3m revenues & expands laboratory

July 16, 2017

Canadian-based specialists to reformulate monepantel

June 27, 2017

New European patent granted for non-cancer applications

June 7, 2017

PharmAust secures core patent in Japan

June 5, 2017

Phase II trial prelim results demonstrate clinical benefit

May 18, 2017

New patent granted for non-cancer applications

May 16, 2017

PharmAust secures core China patent

May 4, 2017

Appendix 4C - Quarterly Report & Company Update - March 2017

April 13, 2017

Dr Richard Hopkins Appointed as CEO of PharmAust

February 28, 2017

Appendix 4D & Financial Report - Dec 2016

February 28, 2017

Appendix 4C - Quarterly Report & Company Update

January 31, 2017

PharmAust Receives $406K R&D Rebate from ATO

January 30, 2017

Decks in 2017